TM5275 sodium 100 mg | 99.55%
TargetMol
TM5275 sodium
Search Results
TM5275 sodium 50 mg | 99.55%
TargetMol
TM5275 sodium
Buparvaquone 100 mg | 99.60%
TargetMol
Buparvaquone is a hydroxynaphthoquinone antiprotozoal drug related to atovaquone and parvaquone.
More Information Supplier PageBuparvaquone
SRI-011381 2 mg | 99.11%
TargetMol
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.
More Information Supplier PageSRI-011381
CD437 2 mg | 99.63%
TargetMol
CD437
SRI-011381 100 mg | 99.11%
TargetMol
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.
More Information Supplier PageSRI-011381
SRI-011381 50 mg | 99.11%
TargetMol
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.
More Information Supplier PageSRI-011381
SRI-011381 25 mg | 99.11%
TargetMol
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.
More Information Supplier PageSRI-011381
SRI-011381 10 mg | 99.11%
TargetMol
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.
More Information Supplier PageSRI-011381
SRI-011381 5 mg | 99.11%
TargetMol
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer’s disease.
More Information Supplier PageSRI-011381